Idera Pharmaceuticals downgraded by HC Wainwright & Co.
$IDRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
HC Wainwright & Co. downgraded Idera Pharmaceuticals from Buy to Neutral
Save time and jump to the most important pieces.
Wedbush downgraded Idera Pharma from Outperform to Neutral and set a new price target of $1.00 from $8.00 previously
Barclays downgraded Idera Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $2.00 from $10.00 previously
JMP Securities downgraded Idera Pharmaceuticals from Outperform to Market Perform